Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosemary E Gale

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Current Hematology Reports|August 7, 2003
Pathogenic markers in essential thrombocythemiaRosemary E Gale
International Journal of Hematology|November 15, 2002
Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PVRosemary E Gale
British Journal of Haematology|June 10, 2008
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcomeClaire Green, David C Linch, Rosemary E Gale
Journal of Cellular Biochemistry|October 14, 2016
Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLCAkbar Ali, Rosemary E Gale, Abdul Rauf Shakoori
British Journal of Haematology|August 6, 2003
Flt3 mutations and leukaemiaPanagiotis D Kottaridis, Rosemary E Gale, David C Linch
Hematology (Amsterdam, Netherlands)|May 15, 2003
Neutrophil elastase mutations in congenital neutropeniaPhil J Ancliff, Rosemary E Gale, David C Linch
Leukemia & Lymphoma|July 12, 2003
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemiaPanagiotis D Kottaridis, Rosemary E Gale, David C Linch
British Journal of Haematology|February 19, 2009
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemiaJonathan R Lambert, Rosemary E Gale, David C Linch
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
Blood|August 21, 2014
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutationsChristopher Allen, Jonathan R Lambert, David C Linch, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Current Hematology Reports|August 7, 2003
Pathogenic markers in essential thrombocythemiaRosemary E Gale
International Journal of Hematology|November 15, 2002
Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PVRosemary E Gale
British Journal of Haematology|June 10, 2008
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcomeClaire Green, David C Linch, Rosemary E Gale
Journal of Cellular Biochemistry|October 14, 2016
Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLCAkbar Ali, Rosemary E Gale, Abdul Rauf Shakoori
British Journal of Haematology|August 6, 2003
Flt3 mutations and leukaemiaPanagiotis D Kottaridis, Rosemary E Gale, David C Linch
Hematology (Amsterdam, Netherlands)|May 15, 2003
Neutrophil elastase mutations in congenital neutropeniaPhil J Ancliff, Rosemary E Gale, David C Linch
Leukemia & Lymphoma|July 12, 2003
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemiaPanagiotis D Kottaridis, Rosemary E Gale, David C Linch
British Journal of Haematology|February 19, 2009
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemiaJonathan R Lambert, Rosemary E Gale, David C Linch
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
Blood|August 21, 2014
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutationsChristopher Allen, Jonathan R Lambert, David C Linch, et al.
Pageof 8